NCU 304
Alternative Names: C5 OHPLatest Information Update: 27 Aug 2002
Price :
$50 *
At a glance
- Originator Nonindustrial source
- Class Antineoplastics; Cyclohexanes; Platinum complexes; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 23 Feb 1999 An abstract has been added to the pharmacodynamics section
- 14 Jul 1998 Profile reviewed
- 11 May 1995 Preclinical development for Cancer in Japan (Unknown route)